Literature DB >> 20739878

Blood groups and susceptibility to virus infection: new developments.

Donald R Branch1.   

Abstract

PURPOSE OF REVIEW: Histo-blood group antigens belonging to the P1PK and GLOB blood group systems are involved in bacterial infections, but a substantial body of evidence is emerging that some of these glycosphingolipids play a role in HIV infection. These recent findings have raised additional questions regarding the possible role of the P/Gb3 histo-blood group antigen in HIV-1 infection. RECENT
FINDINGS: Early studies implicated a number of glycosphingolipids able to interact with HIV envelope glycoprotein 120. It has been recently reported that cellular or soluble P/Gb3 histo-blood group antigen provides protection from HIV-1 infection. This resistance mechanism appears to be mediated through inhibition of fusion of the HIV-1 envelope to the cell target membrane. Protection has been shown to be provided to both HIV-1 X4 and R5 tropic strains. Indeed, an inverse correlation has been documented between the expression of P/Gb3 on the cellular membrane and susceptibility to HIV infection. Moreover, soluble P/Gb3 analogues have been shown to inhibit HIV infection.
SUMMARY: The P/Gb3 histo-blood group antigen is the first described cell surface expressed natural resistance factor for prevention of HIV infection. Increased expression of P/Gb3 correlates to decreased HIV infection, whereas decreased or absent P/Gb3 increases HIV susceptibility. Soluble P/Gb3 analogues can inhibit HIV by two mechanisms: direct inhibition of the free virus and inhibition of viral entry. Future development of soluble P/Gb3 analogues, pharmacologic means of increasing cell surface expression of P/Gb3 on HIV susceptible target cells or both may result in novel therapeutic modalities for the prevention and eradication of HIV/AIDS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20739878     DOI: 10.1097/MOH.0b013e32833ece31

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  8 in total

Review 1.  Blood Groups in Infection and Host Susceptibility.

Authors:  Laura Cooling
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

2.  Association of ABO and Rh Blood Groups to Blood-Borne Infections among Blood Donors in Tehran-Iran.

Authors:  Fatemeh Mohammadali; Aliakbar Pourfathollah
Journal:  Iran J Public Health       Date:  2014-07       Impact factor: 1.429

3.  Blood Group Antigens C, Lub and P1 May Have a Role in HIV Infection in Africans.

Authors:  Modisa Sekhamo Motswaledi; Ishmael Kasvosve; Oluwafemi Omoniyi Oguntibeju
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

4.  Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China.

Authors:  Xuehua Zheng; Xia Rong; Ying Feng; Xikui Sun; Liang Li; Qian Wang; Min Wang; Wenkuan Liu; Chufang Li; Yiyu Yang; Rong Zhou; Jiahai Lu; Liqiang Feng; Ling Chen
Journal:  Emerg Microbes Infect       Date:  2017-06-07       Impact factor: 7.163

5.  ABO blood groups and hepatitis B virus infection: a systematic review and meta-analysis.

Authors:  Wenzhan Jing; Siyu Zhao; Jue Liu; Min Liu
Journal:  BMJ Open       Date:  2020-02-02       Impact factor: 2.692

6.  Prevalence and Association of Transfusion Transmitted Infections with ABO and Rh Blood Groups among Blood Donors at the National Blood Bank, Amman, Jordan.

Authors:  Amir M Al Hroob; Sultan A M Saghir; Amer A Almaiman; Omar S A Alsalahi; Abdullah S Al-Wajeeh; Omar Y A Al-Shargi; Nader Al-Balagi; Ayman M Mahmoud
Journal:  Medicina (Kaunas)       Date:  2020-12-16       Impact factor: 2.430

Review 7.  Histo-blood group glycans in the context of personalized medicine.

Authors:  Viktoria Dotz; Manfred Wuhrer
Journal:  Biochim Biophys Acta       Date:  2015-12-31

8.  Relationship of SARS-CoV-2 Pandemic with Blood Groups.

Authors:  Didar Yanardag Acik; Mehmet Bankir
Journal:  Transfus Med Hemother       Date:  2021-04-07       Impact factor: 3.747

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.